Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 6/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2942086 | 0.90 | AKR1C3 (0.42) | AKR1C3AKR1C2ADRB1ADRB3EGFR | |
| SCHEMBL2943477 | 0.77 | ADRB1 (0.45) | ADRB1ADRB3EGFR | |
| SCHEMBL2949557 | 0.76 | ADRB1 (0.48) | ADRB1ADRB3EGFR | |
| SCHEMBL7676021 | 0.75 | ACHE (0.48) | ADRB1ADRB3EGFR | |
| SCHEMBL2949356 | 0.74 | ADRB1 (0.51) | SRD5A2ADRB1ADRB3EGFR | |
| SCHEMBL25125397 | 0.70 | CA1 (0.58) | EGFR | |
| SCHEMBL29788231 | 0.69 | SRD5A2 (0.59) | AKR1C3AKR1C2SRD5A2ADRB1ADRB3 | |
| SCHEMBL29788333 | 0.69 | CCNT1 (0.55) | EGFR | |
| SCHEMBL2039640 | 0.69 | CCNT1 (0.55) | EGFR | |
| SCHEMBL2039483 | 0.69 | SRD5A2 (0.59) | AKR1C3AKR1C2SRD5A2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | AKR1C3 3197/4885AKR1C2 2588/4885SRD5A2 2279/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | AKR1C3 3200/4885AKR1C2 2650/4885SRD5A2 2301/4885 |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | AKR1C3 3606/4885AKR1C2 3015/4885SRD5A2 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.